Related Experiment Videos
[Endocrine changes in gestagen treatment in a patient with scleroderma diffusa]
Summary
Gestagen and corticosteroid treatment in a male patient with diffuse scleroderma led to decreased gonadotrophins and increased prolactin. Steroid hormone levels were altered, suggesting pituitary suppression and reduced testicular steroid secretion.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Pharmacology
Context:
- A male patient with diffuse scleroderma was treated with gestagens and corticosteroids.
- Longitudinal endocrine monitoring over two years was performed.
Purpose:
- To investigate the endocrine alterations resulting from gestagen and corticosteroid therapy in a male patient with diffuse scleroderma.
- To assess the impact of this treatment on pituitary and steroid hormone levels.
Summary:
- Treatment resulted in decreased plasma gonadotrophin levels and increased prolactin.
- Significant reductions were observed in testosterone, dehydroepiandrosterone (DHEA), and 17-alpha-hydroxyprogesterone levels.
- Estradiol and androstenedione levels remained unchanged during the treatment period.
Impact:
- The observed endocrine changes suggest a suppression of pituitary function.
- This pituitary suppression likely leads to a subsequent decrease in testicular and adrenal steroid secretion.
- Findings highlight potential hormonal side effects of gestagen and corticosteroid therapy in scleroderma patients.